Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug;84(2):194-7.
doi: 10.1038/clpt.2008.123.

Nonprofit biomedical companies

R M Conti  1 , D O Meltzer, M J Ratain
Affiliations

Nonprofit biomedical companies

R M Conti et al. Clin Pharmacol Ther. 2008 Aug.

Abstract

Nonprofit biomedical firms are an integrated market-based solution to improve incentives for investment in promising scientific areas that have high social value but minimal potential for profit. We briefly review the current market with an emphasis on the financing of innovative product development and propose ideas for new nonprofit companies centered on the health concerns of developed countries. We conclude with a suggestion that opportunities exist for nonprofit firms focused on cancer diagnostics, given the limitations of current financing incentives and ripe scientific opportunity.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

Dr. Conti and Dr. Meltzer declared no conflict of interest. Dr. Ratain receives royalties related to pharmacogenetic testing before the prescribing of irinotecan. In addition, he is a co-inventor on several pending pharmacogenetic patents and a director of AspenBio Pharma, a public biotechnology company.

References

    1. BioWorld. [Accessed 28 April 2008];2008 < http://www.bioworld.com>.
    1. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Affairs. 2006;25:420–428. - PubMed
    1. Czerepak A, Ryser S. Drug approvals and failures: implications for alliances. Nat Rev Drug Discov. 2008;7:197–198.
    1. National Science Foundation. Science and Technology Indicators 2008, Chapter 6: Industry, Technology, and the Global Marketplace. 2008 < http://www.nsf.gov/statistics/seind08/c6/c6h.htm>.
    1. Kaitin KI. Obstacles and opportunities in new drug development. Clin Pharmacol Ther. 2008;83:210–212. - PubMed

MeSH terms

LinkOut - more resources